Abstract B103: Integrative genomic and proteomic analyses identify novel targets for Lkb1 deficient metastatic lung tumors
作者
Julián Carretero,Takeshi Shimamura,Klarisa Rikova,Ting‐Lei Gu,Christa L. Borgman,S. Buttarazzi,Kate L. McNamara,Kathleyn A. Brandstetter,Jeffrey C. Silva,Geoffrey Ira Shapiro,Diego H. Castrillón,Sauveur-Michel Maira,Carlos Garcia-Echeverria,Carla F. Kim,Nabeel M. Bardeesy,Norman E. Sharpless,William Y. Kim,Jeffrey A. Engelman,Kwok‐Kin Wong
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research] 日期:2009-12-01卷期号:8 (12_Supplement): B103-B103被引量:4
标识
DOI:10.1158/1535-7163.targ-09-b103
摘要
Abstract Lung cancer is the leading cause of cancer related mortality worldwide. Gene expression profiling of primary human lung tumors has successfully led to the identification of aberrant signalling pathways involved in the initiation of non-small cell lung cancer (NSCLC). However, advances in defining the pathways deregulated in lung cancer progression and metastases have been limited. The process of tumor metastasis is a complex, multistage process that involves both metastasis initiation functions, such as invasion and angiogenesis, as well as metastasis progression functions such as extravasation and survival. In mice, lung-specific deletion of the Lkb1 tumor suppressor gene and activation of mutant Kras results in lung tumors with a high penetrance of lymph node and distant metastases. However, which of the several candidate pathways are responsible for the pro-metastatic effects of Lkb1 loss has yet to be defined. To identify altered signal transduction pathways involved in the progression and metastases of Lkb1 deficient lung tumors we have integrated genomic and phosphoproteomic signatures of primary and metastastic, Lkb1 deficient lung tumors to identify differentially activated signal transduction pathways. These studies revealed a number of signatures associated with the process of metastasis such as EMT, stem cell phenotype, growth factor signaling and focal adhesion. Moreover, several tyrosine kinases, including the non-receptor tyrosine kinase Src and the focal adhesion kinase, are activated in Lkb1 deficient primary and metastatic lung tumors, resulting in increased motility and Src-dependent adhesion of LKB1 deficient cells. Collectively, these results point towards a mechanism behind the increased propensity for metastases seen in Lkb1 deficient lung tumors and identify molecularly targetable pathways for the treatment of LKB1 deficient NSCLC in humans. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B103.